• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form DEFA14A filed by Trevi Therapeutics Inc.

    4/29/25 11:30:18 AM ET
    $TRVI
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $TRVI alert in real time by email
    DEFA14A
    false0001563880DEFA14A00015638802024-01-012024-12-31

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

    SCHEDULE 14A

    Proxy Statement Pursuant to Section 14(a) of the

    Securities Exchange Act of 1934

    (Amendment No. )

    Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐

    Check the appropriate box:

     

     

    ☐

    Preliminary Proxy Statement

    ☐

    Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))

    ☐

    Definitive Proxy Statement

    ☒

    Definitive Additional Materials

    ☐

    Soliciting Material under §240.14a-12

    TREVI THERAPEUTICS, INC.

    (Name of Registrant as Specified In Its Charter)

    (Name of Person(s) Filing Proxy Statement, if other than the Registrant)

    Payment of Filing Fee (Check all boxes that apply):

    ☒

    No fee required.

    ☐

    Fee paid previously with preliminary materials.

    ☐

    Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11.

     


     

    Your Vote Counts! TREVI THERAPEUTICS, INC. 2025 Annual Meeting Vote by June 10, 2025 11:59 PM ET TREVI THERAPEUTICS, INC. 195 CHURCH STREET, 16TH FLOOR NEW HAVEN, CT 06510 V72233-P29416 You invested in TREVI THERAPEUTICS, INC. and it’s time to vote! You have the right to vote on proposals being presented at the Annual Meeting. This is an important notice regarding the availability of proxy materials for the stockholder meeting to be held on June 11, 2025. Get informed before you vote View the Notice and Proxy Statement and Form 10-K online OR you can receive a free paper or email copy of the material(s) by requesting prior to May 28, 2025. If you would like to request a copy of the material(s) for this and/or future stockholder meetings, you may (1) visit www.ProxyVote.com, (2) call 1-800-579-1639 or (3) send an email to [email protected]. If sending an email, please include your control number (indicated below) in the subject line. Unless requested, you will not otherwise receive a paper or email copy. For complete information and to vote, visit www.ProxyVote.com Control # Vote in Advance of the Meeting Vote by June 10, 2025 11:59 PM ET Visit www.ProxyVote.com Vote Virtually at the Meeting* June 11, 2025 1:00 p.m. Eastern Time Smartphone users Point your camera here and vote without entering a control number Virtually at: www.virtualshareholdermeeting.com/TRVI2025 *Please check the meeting materials for any special requirements for meeting attendance.

    img25529448_0.jpg

    Vote at www.ProxyVote.com THIS IS NOT A VOTABLE BALLOT This is an overview of the more complete proxy materials, which contain important information and are available to you on the Internet at www.proxyvote.com. Please follow the instructions on the reverse side to vote these important matters. Board Voting Items Recommends 1.Election of two Class III directors to our Board of Directors, each to serve until the 2028 Annual Meeting of Stockholders. Nominees: 1a.Jennifer Good For1b.Anne VanLentFor2.Ratification of the appointment of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2025.For3.Approval, on an advisory basis, of the compensation paid to our named executive officers.For4.Approval, on an advisory basis, of the frequency of future advisory votes to approve the compensation paid to our named executive officers.1Year5.Approval of an amendment to the Trevi Therapeutics, Inc. 2019 Stock Incentive Plan to increase the number of shares available for issuance under the plan by 6,000,000 shares of common stock, and make certain other amendments. For NOTE: Transaction of any other business properly brought before the Annual Meeting or any adjournment or postponement of the Annual Meeting. Prefer to receive an email instead? While voting on www.ProxyVote.com, be sure to click “Delivery Settings”. V72234-P29416

     


     

    img25529448_1.jpg

     

     


    Get the next $TRVI alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $TRVI

    DatePrice TargetRatingAnalyst
    11/13/2025$13.00Outperform
    Leerink Partners
    8/21/2025$18.00Overweight
    Morgan Stanley
    7/1/2025$25.00Overweight
    Cantor Fitzgerald
    5/28/2025$21.00Buy
    H.C. Wainwright
    3/10/2025$9.00 → $29.00Outperform → Strong Buy
    Raymond James
    3/10/2025$8.00 → $25.00Buy
    Needham
    12/12/2024$6.00 → $7.50Buy
    H.C. Wainwright
    9/9/2024$6.00 → $7.00Outperform
    Leerink Partners
    More analyst ratings

    $TRVI
    SEC Filings

    View All

    SEC Form SCHEDULE 13G filed by Trevi Therapeutics Inc.

    SCHEDULE 13G - Trevi Therapeutics, Inc. (0001563880) (Subject)

    2/5/26 1:40:12 PM ET
    $TRVI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SCHEDULE 13G filed by Trevi Therapeutics Inc.

    SCHEDULE 13G - Trevi Therapeutics, Inc. (0001563880) (Subject)

    1/30/26 2:43:46 PM ET
    $TRVI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Trevi Therapeutics Inc. filed SEC Form 8-K: Leadership Update

    8-K - Trevi Therapeutics, Inc. (0001563880) (Filer)

    12/5/25 8:58:00 AM ET
    $TRVI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $TRVI
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Chief Financial Officer Hastings David C

    4 - Trevi Therapeutics, Inc. (0001563880) (Issuer)

    1/12/26 4:05:09 PM ET
    $TRVI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 3 filed by new insider Hastings David C

    3 - Trevi Therapeutics, Inc. (0001563880) (Issuer)

    1/12/26 4:03:17 PM ET
    $TRVI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Officer Galletta Christopher exercised 4,225 shares at a strike of $0.51, increasing direct ownership by 19% to 26,095 units (SEC Form 4)

    4 - Trevi Therapeutics, Inc. (0001563880) (Issuer)

    12/3/25 4:16:39 PM ET
    $TRVI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $TRVI
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Leerink Partners initiated coverage on Trevi Therapeutics with a new price target

    Leerink Partners initiated coverage of Trevi Therapeutics with a rating of Outperform and set a new price target of $13.00

    11/13/25 9:10:57 AM ET
    $TRVI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Morgan Stanley initiated coverage on Trevi Therapeutics with a new price target

    Morgan Stanley initiated coverage of Trevi Therapeutics with a rating of Overweight and set a new price target of $18.00

    8/21/25 8:19:41 AM ET
    $TRVI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Cantor Fitzgerald initiated coverage on Trevi Therapeutics with a new price target

    Cantor Fitzgerald initiated coverage of Trevi Therapeutics with a rating of Overweight and set a new price target of $25.00

    7/1/25 8:23:22 AM ET
    $TRVI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $TRVI
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Trevi Therapeutics Announces Publication of Data from the Phase 2b IPF Chronic Cough Trial of nalbuphine ER in the Journal of the American Medical Association (JAMA)

    Statistically-significant reduction in the relative change from baseline in 24-hour objective cough frequency observed across all dose groups of nalbuphine ER at Week 6 with statistically-significant cough reduction as early as Week 2, the first time point measured Over 60% of nalbuphine ER-treated patients achieved at least a 50% reduction in 24-hour cough frequency at Week 6 vs baseline Patient-reported outcome measure of cough frequency was consistent with reduction observed with objective cough monitoring NEW HAVEN, Conn., Jan. 22, 2026 /PRNewswire/ -- Trevi Therapeutics, Inc. (NASDAQ:TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy oral nalbuphine

    1/22/26 12:30:00 PM ET
    $TRVI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Trevi Therapeutics Provides Strategic Updates Ahead of Annual LifeSci Partners Corporate Access Event Held During the J.P. Morgan Healthcare Conference

    FDA End-of-Phase 2 meeting scheduled to take place in the first quarter of 2026 for the chronic cough program in patients with idiopathic pulmonary fibrosis Phase 2b refractory chronic cough trial planned to initiate in the first half of 2026 NEW HAVEN, Conn., Jan. 8, 2026 /PRNewswire/ -- Trevi Therapeutics, Inc. (NASDAQ:TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine ER) for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF), non-IPF interstitial lung disease (non-IPF ILD), and refractory chronic cough (RCC), today announced strategic updates ahead of its participation in the 15th Annual Lif

    1/8/26 7:30:00 AM ET
    $TRVI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Trevi Therapeutics Announces Appointment of David Hastings as Chief Financial Officer

    Experienced biotech CFO to lead financial strategy and contribute to the Company's next stage of growth NEW HAVEN, Conn., Dec. 4, 2025 /PRNewswire/ -- Trevi Therapeutics, Inc. (NASDAQ:TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine ER) for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF), non-IPF interstitial lung disease (non-IPF ILD), and refractory chronic cough (RCC), today announced that David Hastings will assume the role of Chief Financial Officer effective January 6, 2026.  www.trevitherapeutics.com (PRNewsfoto/Trevi

    12/4/25 7:30:00 AM ET
    $TRVI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $TRVI
    Leadership Updates

    Live Leadership Updates

    View All

    Trevi Therapeutics Announces Appointment of David Hastings as Chief Financial Officer

    Experienced biotech CFO to lead financial strategy and contribute to the Company's next stage of growth NEW HAVEN, Conn., Dec. 4, 2025 /PRNewswire/ -- Trevi Therapeutics, Inc. (NASDAQ:TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine ER) for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF), non-IPF interstitial lung disease (non-IPF ILD), and refractory chronic cough (RCC), today announced that David Hastings will assume the role of Chief Financial Officer effective January 6, 2026.  www.trevitherapeutics.com (PRNewsfoto/Trevi

    12/4/25 7:30:00 AM ET
    $TRVI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Avalo Therapeutics Appoints Michael Heffernan as Chairman of the Board

    WAYNE, Pa. and ROCKVILLE, Md., March 26, 2025 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (NASDAQ:AVTX), a clinical-stage biotechnology company dedicated to treating immune dysregulation, today announced the appointment of Michael Heffernan as Chairman of the Board of Directors ("Board"). Mr. Heffernan will succeed Dr. Garry Neil as Chairman of the Board. Dr. Neil will continue as a Board member and Chief Executive Officer (CEO) of the Company. "We are thrilled to welcome Michael to Avalo's Board of Directors during this pivotal time in our Company's growth," said Dr. Garry Neil, CEO of Avalo Therapeutics. "Michael's extensive experience in building and leading biopharmaceutical companie

    3/26/25 7:00:00 AM ET
    $AVTX
    $BHVN
    $COLL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Trevi Therapeutics Announces Appointment of James V. Cassella, Ph.D., as Chief Development Officer

    NEW HAVEN, Conn., Sept. 30, 2024 /PRNewswire/ -- Trevi Therapeutics, Inc. (NASDAQ:TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine ER) for the treatment of chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC), today announced the appointment of James V. Cassella, Ph.D., as Chief Development Officer (CDO).  www.trevitherapeutics.com (PRNewsfoto/Trevi Therapeutics, Inc.)" alt="Trevi Therapeutics, Inc. www.trevitherapeutics.com (PRNewsfoto/Trevi Therapeutics, Inc.)"> "I am delighte

    9/30/24 5:30:00 PM ET
    $TRVI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $TRVI
    Financials

    Live finance-specific insights

    View All

    Trevi Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Updates

    Company preparing to initiate comprehensive Phase 3 program for chronic cough in patients with idiopathic pulmonary fibrosis in first half of 2026 Company ended the third quarter of 2025 with $194.9 million in cash, cash equivalents and marketable securities with expected cash runway into 2028 Management to host a conference call and webcast today at 4:30 p.m. EST NEW HAVEN, Conn., Nov. 13, 2025 /PRNewswire/ -- Trevi Therapeutics, Inc. (NASDAQ:TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine ER) for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF), non-IPF interstitial lung disease (non-IPF I

    11/13/25 4:05:00 PM ET
    $TRVI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Trevi Therapeutics to Report Third Quarter 2025 Financial Results and Provide a Corporate Update on November 13, 2025

    Conference call and webcast to be held at 4:30 p.m. ET NEW HAVEN, Conn., Nov. 6, 2025 /PRNewswire/ -- Trevi Therapeutics, Inc. (NASDAQ:TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine ER) for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF), non-IPF interstitial lung disease (non-IPF ILD), and refractory chronic cough (RCC), today announced that senior management will host a conference call and live audio webcast on Thursday, November 13, 2025, at 4:30 p.m. ET, to provide a corporate update and review the Company's financial results for the quarter ended September 30, 2025. 

    11/6/25 4:05:00 PM ET
    $TRVI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Trevi Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Updates

    Announced positive topline results from its Phase 2b CORAL trial of Haduvio for the treatment of chronic cough in patients with IPF Closed $115 million underwritten offering with expected cash runway into 2029 Management to host a conference call and webcast today at 4:30 p.m. ET    NEW HAVEN, Conn., Aug. 7, 2025 /PRNewswire/ -- Trevi Therapeutics, Inc. (NASDAQ:TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine ER) for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF), non-IPF interstitial lung disease (non-IPF ILD), and refractory chronic cough (RCC), today announced financial results for the

    8/7/25 4:05:00 PM ET
    $TRVI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $TRVI
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Trevi Therapeutics Inc.

    SC 13G/A - Trevi Therapeutics, Inc. (0001563880) (Subject)

    11/14/24 5:51:58 PM ET
    $TRVI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Trevi Therapeutics Inc.

    SC 13G/A - Trevi Therapeutics, Inc. (0001563880) (Subject)

    11/13/24 4:30:24 PM ET
    $TRVI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13D/A filed by Trevi Therapeutics Inc.

    SC 13D/A - Trevi Therapeutics, Inc. (0001563880) (Subject)

    11/8/24 6:57:55 PM ET
    $TRVI
    Biotechnology: Pharmaceutical Preparations
    Health Care